Top 5 Casino Stocks To Own For 2017


When Shutterfly Inc. (NASDAQ: SFLY) released its fourth-quarter earnings report after the markets closed on Wednesday, the company said it had $2.63 in earnings per share (EPS) and $561.2 million in revenue. The consensus estimates had called for $2.84 in EPS and revenue of $586.4 million. In the same period of last year, it posted EPS of $3.57 and $548.1 million in revenue.

Revenues for the quarter broke down into consumer net revenues totaling $521.5 million, a year over year increase of 4%, and business solutions net revenues of $39.7 million, a decrease of 11%.


During the quarter, transacting customers totaled 6.2 million, up 1% from last year, while orders increased by 6% to 10.9 million.

In terms of guidance for the first quarter, the company expects to see a net loss of $0.95 to $1.00 per share and net revenues between$185 million and $190 million. The consensus estimates are a net loss of $0.84 per share and $199.36 million in revenue.

Top 5 Casino Stocks To Own For 2017: Coherus BioSciences, Inc.(CHRS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:

    Agence France-Presse/Getty Images

    The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…


    Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.

    Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.

Top 5 Casino Stocks To Own For 2017: ZTE Corporation (ZTCOF)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The United States has a history of preventing Chinese companies that are even suspected of being state-owned from selling certain products into key industries. Huawei and ZTE (OTCPK:ZTCOF), for example, were under harsh scrutiny for their telecommunications equipment.

  • [By SEEKINGALPHA.COM]

    Chinese telco equipment giant ZTE (OTCPK:ZTCOF) has been actively cooperating and communicating with relevant U.S. government departments in order to reach a conclusion of the investigation related to the compny’s violations of sanctions on Iran.

Top 5 Casino Stocks To Own For 2017: The Hain Celestial Group, Inc.(HAIN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Hain Celestial Group (HAIN) has jumped 13% to $40.40 after announcing that an independent review found no evidence that accounting errors were intentional.

  • [By Peter Graham]

    A long term performance chart shows shares of United Natural Foods,Whole Foods Market and The Hain Celestial Group, Inc (NASDAQ: HAIN),a previous SmallCap Network Elite Opportunity (SCN EO) portfolio pick, all having similar looking charts albeit HAIN has performed better:

  • [By Brian Stoffel]

    Shareholders of Hain Celestial (NASDAQ:HAIN) have endured a stomach-churning year. In August, the company announced that it would have to delay filing its quarterly report, saying: “The Company is currently evaluating whether the revenue associated with [Concessions that were granted to certain distributors]was accounted for in the correct period.”

  • [By Peter Graham]

    A long term performance chart shows shares of United Natural Foods,Whole Foods Market and The Hain Celestial Group, Inc (NASDAQ: HAIN),a previous SmallCap Network Elite Opportunity (SCN EO) portfolio pick, all having similar looking chartswith HAIN being the better performer:

Top 5 Casino Stocks To Own For 2017: Apricus Biosciences, Inc(APRI)


Advisors’ Opinion:

  • [By Jon C. Ogg]

    The biotechs and emerging pharma havebeen under pressure from politicians attacking drug prices. That doesn’t mean that there are not some big winners out there. Sometimes the biggest winners are companies most investors have never heard of. Even if you have been a biotech and emerging pharma investor for years, chances are high that you would have never heard of a small outfit called Apricus Biosciences Inc. (NASDAQ: APRI).

Top 5 Casino Stocks To Own For 2017: Mayne Pharma Group Limited (MAYNF)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ:ENDP), Sun Pharmaceutical Industries (OTC:SMPQY), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), and Mayne (OTCPK:MAYNF). This shows that generics are not immune from criticism and price discussions. However, in our opinion, they are safer because they might be the solution to the high-price problem.

Leave a Reply

Your email address will not be published. Required fields are marked *